A Study of LM-24C5 for Advanced Solid Tumors
This study is testing a new treatment called LM-24C5 for people with advanced solid tumors. LM-24C5 is given through an IV and works by targeting the immune system, specifically using a monoclonal antibody and affecting the RAF pathway. The main goal is to see how safe LM-24C5 is and to find the best dose. Researchers will be looking for any side effects or serious problems over 60 weeks. You may be able to join if you are at least 18 years old, have advanced solid tumors, and are willing to sign an informed consent form. The study plans to enroll about 49 participants, but its current recruitment status is unclear.
- Study design
- This study is testing LM-24C5 in about 49 participants with advanced solid tumors. It is an interventional study, meaning participants will receive the study drug.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track adverse events, dose-limiting toxicity, and serious adverse events for 60 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of LM-24C5 For Advanced Solid Tumors
At a glance
Conditions
NCT06187402
Where you'd take part
This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Indiana University Melvan and Bren Simon Cancer Center
Indianapolis, Indianano site contact published
Not yet recruiting
Mary Crowley Cancer Research Center
Dallas, Texasno site contact published
Not yet recruiting
Ocala Oncology
Ocala, Floridano site contact published
Recruiting
The Christ Hospital
Cincinnati, Ohiono site contact published
Not yet recruiting
University of Southern California (USC) - Norris Comprehensive Cancer Center
Los Angeles, Californiano site contact published
Not yet recruiting
Virginia Cancer Specialists, P.C.
Fairfax, Virginiano site contact published
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Terry Pang · STUDY_DIRECTOR · LaNova
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of adverse events (AEs)60 weeks
Phase 1
- Incidence of dose-limiting toxicity (DLT)60 weeks
Phase 1
- Incidence of serious adverse event (SAE)60 weeks
Phase 1
- Ear Temperature60 weeks
Phase 1
- Pulse in BPM(Beat per Minute)60 weeks
Phase 1
- Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure)60 weeks
Phase 1
- Number of participants with abnormal Hematology test results60 weeks
Phase 1
- Number of participants with abnormal Urinalysis test results60 weeks
Phase 1
- Number of participants with abnormal Blood Biochemistry test results60 weeks
Phase 1
- Number of participants with abnormal Coagulation test results in PT(Prothrombin time), APTT(Activated partial thromboplastin time), FIB(Fibrinogen), TT(Thrombin time) and INR(International normalized ratio).60 weeks
Phase 1
- Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage60 weeks
Phase 1
- 12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.60 weeks
Phase 1
- ECOG(Eastern Cooperative Oncology Group) score60 weeks
Phase 1
- Overall Response Rate (ORR)36 weeks
Phase 2